Meeting Abstracts

Clinical Posters From JADPRO Live 2023

Thirty-three clinical posters focused on the role of the advanced practitioner were presented at JADPRO Live this past November 9 to 12, 2023, in Orlando, Florida. Read the abstracts here, and access the full posters and audio narrations...

ASH Highlights and Commentary: Multiple Myeloma

Kathryn T. Maples, PharmD, BCOP

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Myeloid Malignancies

Lindsey Lyle, MS, PA-C

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Additional Topics of Interest

Sandra E. Kurtin, PhD, ANP-C, AOCN®

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

Gastrointestinal Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Nina N. Grenon, DNP, AGCNP-BC, AOCN®

Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on single and dual immunotherapy for advanced esophageal squamous cell carcinoma; maintenance therapy for metastatic colorectal cancer; a HER2-targeted...

Prostate Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, evaluates research on an investigational radiolabeled small molecule, combination therapy in the treatment of de novo metastatic prostate cancer, and a CYP17-lyase inhibit...

Genitourinary (Non-Prostate) Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Emily Lemke, DNP, AGPCNP-BC, AOCNP®

Following coverage from The ASCO Post, Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of Medical College of Wisconsin Cancer Center, comments on an adjuvant trial of a checkpoint inhibitor for clear cell renal cell carcinoma (RCC), real-world data...

Gynecologic Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Laura Doherty, FNP-BC, AOCNP®

Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island/Brown University, interprets data on adjuvant chemotherapy for locally advanced cervical cancer, bevacizumab for advanced ovarian cancer, a new treatment opti...

Other Solid Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN and Mee-young Lee, MSN, ANP-BC

Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of University of Arizona Cancer Center, considers the implications of a novel monoclonal antibody for nasopharyngeal cancer, and Mee-young Lee, MSN, ANP-BC, of Monter Cancer Center, Northwell, disc...

Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Amber B. Koehler, PA-C, MS, P. Andrew Allred, MS, PA-C, and Donna Catamero, ANP-BC, OCN®, CCRC

With conference reporting provided by The ASCO Post, Amber B. Koehler, PA-C, MS, of Mayo Clinic, evaluates data on BTK inhibitors; fixed-duration, first-line treatment with ibrutinib plus venetoclax; and a novel oral BCL2 antagonist for ...

Issues in Oncology: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Josh Epworth, ARNP

Josh Epworth, ARNP, of University of Washington Medical Center, considers the findings of three important abstracts from the 2021 ASCO Annual Meeting and reflects on how advanced practitioners can improve access and care for their patien...

Disparities and Access to Care: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Amy Pierre, MSN, ANP-BC

Amy Pierre, MSN, ANP-BC, of Flatiron Health and Memorial Sloan Kettering Cancer Center, considers takeaways from a program targeting minority accrual to oncology trials and a study evaluating minority representation in precision oncology...

Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC

Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doubl...

Melanoma: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Lisa Kottschade, APRN, MSN, CNP

With coverage from The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews data on immune therapy after surgery, the combination of the anti–LAG-3 antibody relatlimab and nivolumab, and a 6.5-year update of combination ni...

ASH Highlights and Commentary: Chronic Lymphocytic Leukemia and Lymphomas

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Additional Topics of Interest

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Multiple Myeloma

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2020 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Chronic Lymphocytic Leukemia

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

ASH Highlights and Commentary: Acute Myeloid Leukemia and Myelodysplastic Syndromes

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

Therapeutic Advances in Prostate Cancer

Presented by Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP

Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP, discussed the emerging data regarding the role of genomics in metastatic castration-sensitive and -resistant prostate cancer, as well as strategies to manage the to...

Abstracts From JADPRO Live 2020

The posters for the abstracts below can be found at eventscribe.com/2020/jadprolive/posters/posterWall.asp

Abstracts from JADPRO Live 2019

Abstracts from JADPRO Live 2019 Washington State Convention Center • Seattle • October 24–27 The posters for the abstracts below can be found at: eventscribe.com/2019/posters/JADPROLIVE/home.asp.

Abstracts from JADPRO Live 2018

Abstracts from JADPRO Live 2018 THE DIPLOMAT HOTEL, HOLLYWOOD, FLORIDA • NOVEMBER 1–4, 2018 The posters for the abstracts below can be found at eventscribe.com/2018/posters/JADPROLIVE/home.asp.

Managing the Continuum of Myeloid Malignancies

Advanced practitioners can play an important role in assessing patients with myeloid malignancies for fitness and addressing vulnerabilities so that patients can benefit from allogeneic stem cell transplant, which remains the best option...

JL501. Advanced Practice Provider Delivery of Advance Care Planning Counseling in Community Oncology

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Advanced practice providers...

JL502. An Algorithm for Transitioning Patients From Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets and Sprinkle Granules

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Context: Iron chelation therapy for i...

JL503. Chimeric Antigen Receptor T-Cell Therapy: Management of Toxicities

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Introduction: Relapsed and/or refractor...

JL504. Complex Illness Support Alongside Standard Oncology Care for Patients With Incurable Cancer

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Objective: This was a descriptive stu...

JL505. Coping Strategies of Hematology/Oncology Nurse Practitioners

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Providing care to hematolog...

JL506. Dedicated Advanced Practice Provider in an Outpatient Oncology Infusion Center

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Adverse drug reactions ar...

JL507. Development of a Professional Practice Model for Neuro-Oncology Advanced Practitioners at an Academic Medical Center

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp outstanding Poster Award Backgroun...

JL508. Diversity Awareness and Documentation Practices Among Oncology Advanced Practice Providers: A Prospective Quality Improvement Project

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Health-care providers have ...

JL509. Empowering the Advanced Practitioner to Champion Education of Tumor Lysis Syndrome to the Clinical Nursing Team

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Context: A metabolic emergency related ...

JL510. Febrile Neutropenia Risk Assessment Prior to Chemotherapy and Use of Colony-Stimulating Factor Prophylaxis in U.S. Community Oncology Clinics

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Objective: Current guidelines recomme...

JL511. Hematology/Oncology Nurse Practitioners: A Study of Job Satisfaction, Stress, and Intention to Leave the Specialty

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: The predicted oncology/he...

JL512. Impact Analysis of an Advanced Practice Nurse on Outcomes for an Inpatient Hematological Malignancies Service in an Academic Medical Center

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: The complex care and ma...

JL513. Improving Data Quality and Knowledge Management Through the Application of Artificial Intelligence to Oncology Care Model Patients

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: The Center for Medicare S...

JL515. Intra-Professional Collaboration for Safe Chemotherapy Administration

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: With continuous advanceme...

JL516. Management of Cytokine Release Syndrome and Neurologic Events in ZUMA-1

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp JL516. Management of Cytokine Relea...

JL517. Minimal Residual Disease in Hematological Malignancies: Implications for Practice

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: As advanced practice prov...

JL518. Mistaken Identity: The Soft Tissue Sarcoma Conundrum

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Introduction: Soft tissue sarcoma (...

JL519. Modified Outpatient Regimen of Daratumumab to Reduce First Infusion Reaction Risk

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 Background: Daratumumab (dara) is a CD38 targeting monoclonal antibody with significant activity in multiple myeloma. Infusion-related reacti...

JL520. Oncology Care Model and the Transformation of the APN Role in the Care of Patients Undergoing Chemotherapy

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Objective/Background: The Center for ...

JL521. Oncology Nurse Practitioners’ Beliefs About Evidence-Based Practice and Barriers to Research Utilization

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Purpose/Objectives: To determine th...

JL522. Optimizing Survivorship Care Plan Quality and Efficiency Through Cancer Registry Partnerships

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Objective: Providing survivorship car...

JL523. Outcome Evaluation of Timing Recommendations for Influenza Vaccinations in Patients Receiving Intravenous Chemotherapy

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Objective: The Centers for Disease Co...

JL524. Pharmacy Financial Advocacy: Benefits of a Pharmacy Financial Advocate in the Oncology Clinic

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Comprehensive cancer care...

JL525. Real-World Systemic Therapy Sequences Following a CDK 4/6 Inhibitor Regimen Among Post-Menopausal Women

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp JL525. Real-World Systemic Therapy ...

JL526. Rituximab and Melanoma: A Case Report

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Rituximab is a monoclonal...

JL527. Rural Infusion Centers Gaining Access to Expert Oncology and Infusion Support Through the Use of Telemedicine

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Telemedicine has been des...

JL528. Survivorship Care Planning in a Large, Multi-Clinic Cancer Program

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Aurora Health Care (AHC) ...

JL529. The Advanced Practice Provider and Subcutaneous Rituximab: Implications for Practice

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Rituximab (Rituxan), an a...

JL530. The Creation and Sustainability of an Effective After-Hours Coverage Model Utilizing Advanced Practice Providers

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Background: Located in Houston’s Texa...

JL531. The Expanding Role of Surgical Physician Assistants in Clinical Oncology Research

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Purpose: To present an overview of th...

JL532. The Quantity of Care Provided by Nurse Practitioners and Physician Assistants to Older Adults With Cancer

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Purposes/Aims: The purpose of this st...

JL533. Utilizing the COMFORT Curriculum With Advanced Practice Providers to Enhance the Family Meeting Process and Improve Patient Care

Abstracts From 
JADPRO Live at APSHO 2017Marriott Marquis, Houston, Texas • November 2–5, 2017 The posters for the abstracts below can be found at:eventscribe.com/2017/posters/JADPROLIVE/home.asp Purpose: To implement and evaluate an...

JL401. A Regional Cancer Center’s Experience With Lung Cancer Screening Using Low Dose CT

Background: Lung cancer is often diagnosed late when treatment options are limited. The goal of screening for lung cancer with low dose CT is to diagnose at an earlier stage, when more treatment options including potentially curative sur...

JL402. A Retrospective Study of the Incidence of Vitamin D Insufficiency in BRCA Mutation Carriers in a Community Cancer Center

Introduction: Previous studies have alluded to the beneficial effects of vitamin D, particularly with regard to cancer. Vitamin D has been suggested to decrease negative effects of cancer treatments, hinder growth of tumor cells and redu...

JL403. Advanced Practice and Improved Outcomes for Infusion Therapy Patients Experiencing ADRs

Objective: Our cancer infusion room treats sixty patients per day. Infusions include complex chemotherapy, monoclonal antibodies, and research pharmaceuticals. The high volume of infusions and the complexity of the regimens has led to in...

JL404. An Academic Cancer Center’s Approach to Observation Management Services

Aim: To highlight an academic cancer center’s approach to providing comprehensive care by utilizing a short-stay outpatient observation unit. Background: The Clinical Decision Unit (CDU) is a 16 bed observation unit that focuses on probl...

JL405. An Interdisciplinary Educational Checklist for Allogeneic Stem Transplant Patients

Purpose: To develop and evaluate the use of a comprehensive educational checklist for allogeneic stem cell transplant patients, that will be used by all members of the HSCT interdisciplinary team (IDT) during initial transplant hospitali...

JL406. BMDACC Breast Cancer Program Clinical Rotation for Nurse Practitioner Students

Purpose: To increase awareness and promote understanding of multidisciplinary care for breast cancer patients. Background: Clinical rotations are designed to bridge the gap between didactic and practice. However, there are significant va...

JL407. Burden of Phlebotomy in Patients With Polycythemia Vera in the United States: A Preliminary Analysis of Baseline Data from the REVEAL Study

Background: Phlebotomy is often used to maintain hematocrit < 45% and prevent thrombotic events in patients with polycythemia vera (PV); however, phlebotomy procedures are inconvenient and/or poorly tolerated by some patients. Iron de...

JL408. Decreasing Venous Thromboembolism in Patients With Hematologic Malignancy Through Implementation of Clinical Practice Guidelines – A Quality Improvement Project

Background: Venous thromboembolism (VTE) is a highly prevalent complication in patients with cancer with reported incidence rates ranging between 8-19% (Khorana, Dalal, Lin, & Connolly, 2013). Patients with VTE have at least a 2-fold...

JL409. Development of An Evidence-Based Scorecard to Assess Provider Adherence to Gastrointestinal Toxicity Management

Objective: Gastrointestinal toxicity (GIT) is associated with targeted therapies in cancer treatment. GIT can lead to diminished treatment adherence and poor quality of life. It is among the top causes of emergency room visits and hospit...

JL410. Identification of Continued Educational Gaps Among Oncology Nurses Treating Patients With Pancreatic Cancer: A Case for Further Education

Introduction/Background: In recent years, the treatment paradigm for management of advanced pancreatic cancer has changed dramatically. Because oncology nurses are on the front line of care for patients with pancreatic cancer, we sought ...

JL411. Implementation and Evaluation of an Influenza Adherence Toolkit in Allogeneic Bone Marrow Transplant Recipients

Background: The incidence of influenza in hematopoietic stem cell recipients is 7-35% with a 15-35% mortality rate (Shah et al., 2012). Vinograd et al. (2014) reported a 48% compliance rate in influenza vaccinations. In our NCI-designate...

JL412. Management of Endocrinopathies Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors

Background: Combination therapy with nivolumab (NIVO) and ipilimumab (IPI) is approved for the first-line treatment of advanced melanoma (MEL). Recent phase 1 studies have also shown promising efficacy with NIVO+IPI in patients (pts) wit...

JL413. Management of Gastrointestinal Adverse Events (AEs) Associated With Nivolumab and Ipilimumab Combination Therapy in Solid Tumors

Background: Nivolumab (NIVO) and ipilimumab (IPI) combination therapy is approved for the first-line treatment of advanced melanoma (MEL), and recent phase 1 studies have shown promising efficacy in non-small cell lung cancer (NSCLC) and...

JL414. Multidisciplinary Management of Hepatocellular Carcinoma: The Role of Systemic Chemotherapy and Chemoembolization in Converting Patients With Large Unresectable Liver Tumors to Surgical Resectability

Introduction: HCC is the fifth most common malignant neoplasm in men and ninth most common in women worldwide. Although the incidence of HCC in the United States is rare, the incidence of this particular cancer is rising secondary to the...

JL415. Nurses Championing Exercise in Survivorship Care Clinic Visits

Objective: Breast cancer survivors are highly motivated to make lifestyle changes that enhance health (Urquhart, 2010). Nurses and nurse practitioners (NPs) often provide cancer survivor care and are in an influential position to educate...

JL416. Parathyroid Carcinoma Overview: A Case Study

Introduction: Parathyroid carcinoma is a rare malignancy that can be difficult to diagnose due to clinical features shared with benign primary hyperparathyroidism (PHPT). It accounts for 1% of PHPT cases and has symptoms commonly referre...

JL417. Performance Improvement Continuing Medical Education (CME) for the Advanced Practice Provider in Oncology

Background: Performance improvement (PI) is one of the newest CME learning formats designed for providers to evaluate and make changes to their clinical practice. In 2014, The National Commission on Certification of Physician Assistants ...

JL418. Primary Polycythemia Vera: Advances in Diagnosis and Treatment

Purpose: The purpose of this poster presentation is to educate advanced hematology/oncology practitioners how to diagnose, evaluate thrombotic risk, manage and treat patients with primary polycythemia vera. Background: Primary polycythem...

JL419. Recognizing the Contributions of Advanced Practice Providers to Oncology Care: Are Current Metrics Enough?

Background: The contributions of advance practice providers (APPs) to an oncology practice are complex, and it can be challenging to discern and measure how their unique contributions are impacting their practice. Two terms, productivity...

JL420. Redesigning How We Communicate Important Safety Information (ISI) Using the Universal Patient Language

Background: The Universal Patient Language (UPL), is a set of resources developed by Bristol-Myers Squibb, to help communicate with patients about complex topics. At the core of the UPL are seven foundational principles. BMS applied thes...

JL421. Review of a Genetic Risk Assessment Delivery Model in a Private Community Oncology Practice

According to the Oncology Nursing Society (ONS), part of the advanced practice nurse (APN) role is to provide genetic and genomic care to individuals in conjunction with expert providers (ONS, 2012). This is a review of a genetic risk as...

JL422. Screening for and Managing Distress in Patients With Metastatic Lung Cancer

Patients with metastatic lung cancer experience high levels of distress due to their disease trajectory and treatment. Oncology nurses are experts in patient care and symptom management giving them the opportunity to screen and treat pat...

JL423. Soft Tissue Sarcoma: A Case Study and Multidisciplinary Management

Introduction: Soft tissue sarcoma (STS) is cancer of connective tissues and comprises a collection of over 50 distinct diagnoses. Approximately 11,000 cases are diagnosed in the US each year, accounting for about 1% of all adult cancers....

JL424. The Interrelationship of Polypharmacy on Functional Status and Quality of Life in the Elderly Chronic Lymphocytic Leukemia Patient

Objective: The purpose of this descriptive correlational study was to examine how the number of medications taken on a daily basis by elderly Chronic Lymphocytic Leukemia (CLL) patients is related to their functional status and quality o...

JL425. Tumor Lysis Syndrome: An Electrolyte Emergency

Objective: Tumor lysis syndrome (TLS) refers to the constellation of metabolic disturbances that may follow the initiation of cancer treatment. It can occur in patients with bulky, rapidly proliferating, treatment-responsive tumors such ...

JL426. The Impact of the ONc-PoWER Course on the Professional Development of Nurse Practitioners

Background: The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER) is an online course developed by Margaret Rosenzweig, PhD, FNP-BC, AOCNP® from the University of Pittsburgh School of Nursing and funded by the National Cance...

JL427. The Effect of Prophylactic Naproxen, Prophylactic Loratadine, or No Prophylaxis on Bone Pain in Patients With Breast Cancer Receiving Chemotherapy and Pegfilgrastim

Background: Mild-to-moderate bone pain is the most commonly reported adverse event (AE) associated with pegfilgrastim. Anecdotal reports and some studies have suggested that naproxen (an NSAID) and loratadine (an antihistamine) may help ...

JL428. Symptoms and Management of Cerebral Progression in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC): A Clinical and Nursing Perspective

Background: Around 30–50% of ALK+ NSCLC patients have brain metastases (BM) before initiating ALK inhibitor (ALKi) treatment. In general, the prognosis for patients with BM is poor (median survival 7 months). Standard treatments include ...

JL429. Transfusion Practice Patterns in Patients Receiving Myelosuppressive Chemotherapy for Nonmyeloid Cancer: Results From a Prospective Observational Study

Background: The decision to prescribe a packed red blood cell (PRBC) transfusion in patients with chemotherapy-induced anemia includes assessment of clinical features such as the patient’s cancer type and treatment regimen, severity of s...

JL301. Adherence to Oral Cancer Therapies in the Adult Oncology/Hematology Patient

There has been an increase in the development of oral cancer agents in recent years. This has created a paradigm shift in the management of the adult oncology/hematology population as patients must assume increased responsibility for und...

JL302. The CARE (Clinical Assessment and Rapid Evaluation) Clinic: Improving the Oncology Patient Experience and Outcomes

Oncology patient visits are anticipated to increase annually as the population ages with an estimated 24,540 new cancer diagnoses in Colorado in 2015. This year, University of Colorado Anschutz Cancer Pavilion (ACP) visits have increased...

JL303. Local Observational Study of Supportive Care, Treatment and Bone Health in Prostate Cancer Patients Receiving Androgen Deprivation Therapy (LOSST trial)

Background: Advanced practice nurses (APRNs) caring for prostate cancer patients in a community setting noted that bone health was not being monitored in patients receiving ADT. A review of published articles in early 2011 revealed littl...

JL304. Evaluation of the Oncology Nurse Practitioners Web Education Resource Course

Background: The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER) is an online course developed by Margaret Rosenzweig, PhD, FNP-BC, AOCNP, from the University of Pittsburgh School of Nursing and funded by the National Cance...

JL305. Bringing Quality Into Your Practice

As professionals, we pride ourselves on delivering high quality care. However, until five years ago, there was no method of demonstrating a practice’s level of excellence distinction from competing practices. In 2010, the Quality Oncolog...

JL306. Oncology Nurse Communication Training Needs Across the Cancer Trajectory

Scope of Problem: Understanding care needs across the cancer trajectory requires sensitive communication about diagnosis, discussing factors influencing treatment decision-making, mediating family communication, and psychosocial counseli...

JL307. The Advocacy Connector: Bridging the Gap

Objective: There is a knowledge gap between the capabilities of advocacy groups and healthcare providers (HCPs) and patients. The need to create awareness about valuable resources, available through not-for-profit organizations, for HCPs...

JL308. Utilization of Cancer Screening Guidelines by APRNs

Introduction/Purpose: Utilization of established cancer screening guidelines ensures recommendations that are individualized to a patient’s level of risk. The purpose of this survey was to understand how APRNs in Texas access and utilize...

JL309. Development and Implementation of a Peer Review Process for APRNs

Peer Review is the evaluation of professionals by a peer who practices in a similar role and scope of practice. Yale New Haven Hospital (YNHH) Medical Staff Office utilizes ‘The Joint Commission’ ongoing professional practice evaluation ...

JL310. Pilot Evaluations of Experiences of Early Stage Post-Surgical Lung Cancer Survivors

Background: Over 220,000 patients are diagnosed with lung cancer each year. Although only 15% are diagnosed at an early stage, with the possibility of curative surgery, this population numbers over 165,000 annual survivors. The purpose o...

JL311. Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non–Small Cell Lung Cancer (NSCLC)

Introduction: Targeted therapies for the treatment of metastatic NSCLC are associated with a distinct set of adverse side effects that differ clinically from those seen with chemotherapies. Our institution has been actively involved in c...

JL312. Management of Lung Cancer Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Nivolumab

Introduction: Earlier this year, nivolumab, a fully human IgG4 anti–programmed death-1 (PD-1) immune checkpoint inhibitor antibody, gained approval for advanced-stage squamous-cell lung cancer in patients whose disease progressed after t...

JL313. By Nurses, For Nurses: A Successful Educational Intervention That Addressed the Clinical Challenges of Treating Elderly Patients With Multiple Myeloma

Introduction/Background: Because multiple myeloma (MM) typically occurs in patients over 70 years of age, many patients present with comorbidities. This can present a challenge for the care team who must consider multiple factors which p...

JL314. Patient Reported Symptoms, Concerns and Provider Intervention in Patients With Multiple Myeloma

Introduction: Multiple Myeloma (MM) treatment is undergoing rapid transformation. New agents and regimens create an increased need to proactively screen for, assess, and manage patient reported symptoms and concerns. The Carevive Care Pl...

JL315. The 2014 Mentorship Program: Bridging Communication and Educational Gaps in Multiple Myeloma

Introduction: Significant changes to the multiple myeloma (MM) landscape have occurred within the past 10 years. Keeping up-to-date on drugs to treat MM and the management of side effects is challenging. The 2014 Multiple Myeloma Mentors...

JL316. The APSHO Practice Survey

Background: The Advanced Practitioner Society for Hematology and Oncology (APSHO) conducted a survey of its members over a 6 week period in the summer of 2014 to describe practice patterns. Significance of the Problem: Cancer survivors a...

JL317. Educational and Knowledge Gaps Among Community Healthcare Providers (HCPs) Treating Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Background: MDS represent a heterogeneous group of myeloid malignancies with variable prognosis. MDS are underdiagnosed, and many lower-risk patients are offered only supportive care (Khan AM. Am J Med. 2012;125[7 suppl]:S15-S7). This st...

JL318. Collaborative Interventions in the Treatment of Chemotherapy-Induced Oral Mucositis With Low Level Laser Therapy (LLLT)–A Case Series

Introduction: Oral mucositis refers to the damage of the mouth’s mucosa resulting from chemotherapy or radiation therapy. It is one of the most significantly debilitating, dose-limiting acute toxicities of cancer therapy that not only co...

JL319. Management of Skin Adverse Events (AEs) Associated With Nivolumab and Ipilimumab in Patients With Melanoma: A Nursing Perspective

Introduction: The advent of immune checkpoint inhibitors has substantially improved the treatment of advanced melanoma in the past 5 years. Ipilimumab was the first drug to prolong overall survival, while nivolumab and pembrolizumab have...

JL320. Creation of Metrics for Advanced Practice Providers in an Academic Outpatient Hematology Oncology Practice

Introduction: Much of oncology care is now delivered through a team approach; understanding the potential benefits of the physician/APP collaborative unit, in addition to the value of the APP individually, has never been more important. ...

JL321. Use of Flow Cytometry in Clinical Practice

Advanced practice nurses have played a vital role in progressing and enhancing clinical practice. They have collaborated with many disciplines, including, but not limited to, medicine, biology, sociology, and psychology. These collaborat...

JL322. Overview of Adverse Events (AEs) Seen With Combination of Nivolumab and Ipilimumab

Introduction: Ipilimumab and nivolumab are immune checkpoint inhibitors approved for advanced melanoma. According to clinical trials, combination of these agents has greater efficacy compared with monotherapy. However, both nivolumab and...

JL323. CREAM Principles: The Advanced Nursing Role in the Management of Dermatologic Adverse Events to Anticancer Therapy

Background: Dermatologic adverse events (dAE) can occur during and after all anticancer treatment regimens such as, but not limited to, rashes, nail abnormalities hand and feet symptoms, alopecia, xerosis, pruritus, radiation dermatitis,...

JL324. Identification and Application of Clinical Resources for Advanced Practitioners Supporting the Management of Neutropenia Associated With Palbociclib

Integration of a first-in-class drug into clinical practice generates a need for information to support its safe and effective use. In the early days post-FDA approval, the amount of available information can be limited and knowing how t...

JL325. Pilot Trial of Homebound Stem Cell Transplantation at Memorial Sloan Kettering Cancer Center

System and patient-based barriers lead to the inability of individuals to access appropriate treatment and oncologic care. Establishment of a homebound hematopoietic stem cell transplantation (HSCT) program promotes increased access to c...

JL326. Progress Towards Value in Healthcare: Implementation of Time-Driven Activity-Based Costing (TDABC) in Hematopoietic Stem Cell Transplantation

Background and Specific Aims: As healthcare institutions transition to value-based payment systems, there is an increasing need to identify the true costs of delivering health services. The costing methodology Time-Driven Activity-Based ...

JL327. Survivorship Care Plans: Strategies to Enhance Patient Utility and Value

Introduction: A decade ago the Institute of Medicine recommended that every survivor receive a survivor care plan (SCP) yet despite endorsements of clinical merit, evidence is still evolving regarding SCP utility and value to patients. M...

JL202. PD-1 Pathway Immune Checkpoint Inhibitors: The Next Wave in Immunotherapy for Melanoma

Novel immune checkpoint inhibitors are changing the treatment options for advanced melanoma. Advanced practitioners may be familiar with ipilimumab, which inhibits the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathway. The nex...

JL203. Clinical Practice: Hypercalcemia of Malignancy

Hypercalcemia is a common paraneoplastic syndrome associated with a variety of malignancies including lymphomas, aerodigestive, uterine, endometrial, breast, neuroendocrine, cervical, and renal cell carcinomas. The incidence of hypercalc...

JL204. Efficacy of a Transdermal Granisetron Patch in Controlling Chemotherapy-Induced Nausea and Vomiting (CINV) in Head and Neck Cancer Patients

Objective: To examine the efficacy of a transdermal granisetron patch for controlling CINV in head and neck cancer patients. Significance: Head and neck cancer patients can experience mechanical obstruction or dysphagia making adherence ...

JL205. Differences in Metabolite Activity of the Selective Estrogen Receptor Modulators Tamoxifen and Toremifene: Clinical Implications for Patients with Hormone Receptor Positive Breast Cancer

Objective: To review published data on the metabolism of toremifene and assess any implications for treatment decisions. Significance: The use of selective estrogen receptor modulators (SERMs) forms part of the treatment backbone of horm...

JL206. ONc-PoWER: Oncology Nurse Practitioner Web Education Resource

Background: Nurse practitioners (NP) new to cancer care are entering practice without any standardized oncology curriculum. This gap in knowledge can lead to poor patient outcomes, risk management vulnerabilities, and high clinician attr...

JL207. Decision Making Factors and Outcomes: Cancer Clinical Trials

Background: The Research Decision Making Model guided this completed research on decision making for cancer clinical trial participation. The Research Decision Model was based on Bowling and Ebrahim’s Model for Treatment Decision Making ...

JL208. Medical Orders for Life Sustaining Treatment: Making the Most Out of the MOLSTs

There are several names given across the United States for the orders that direct end of care life. In some states, it is called Medical Orders for Life Sustaining Treatment (MOLST), in other states, Provider (or Physician) Orders for Li...

JL209. Vaccinations Post Hematopoietic Stem Cell Transplantation

Purpose: The purpose of this poster presentation is to educate advanced practice professionals regarding vaccinations post hematopoietic stem cell transplantation and to focus on the standardization and implementation of vaccinations pos...

JL210. Acupuncture for the Management of Hot Flashes in Breast Cancer Survivors

In the United States more women are diagnosed with breast cancer than any other type of cancer. As survival for these women improve health care practitioners must address long-term problems secondary to cancer therapy. The development of...

JL211. PD-1 Immune Checkpoint Inhibitors: An Exciting New Approach for the Treatment of Non-Small Cell Lung Cancer

Programmed death-1 (PD-1) immune checkpoint inhibitors are novel immuno-oncology agents being developed for the treatment of advanced non-small cell lung cancer (NSCLC) and other cancers. Clinical trial data have shown promising antitumo...

JL01. The Role of the Multidisciplinary Tumor Board in the Management of Patient with Gastrointestinal Malignancy

The optimal evaluation and management of the patient with gastrointestinal (GI) malignancy is multimodal, involving coordination between multiple specialties, including radiology, pathology, medical oncology, surgical oncology, radiation...

JL02. Virtual Reality as an Adjunct Method to Alleviate Pain and Anxiety in Patients Undergoing Bone Marrow Procedures

Purpose: The purpose of this randomized controlled study is to determine the clinical feasibility of using virtual reality at the bedside with patients who are undergoing a bone marrow biopsy. Outcome measures included pre and post pain ...

JL03. Adding to Your Tool Box: Holistic Modalities

Significance: Holistic medicine, as defined by the American Holistic Medical Association, “is the art and science of healing that addresses care of the whole person—body, mind, and spirit.” The practice of holistic medicine integrates co...

JL04. Adjuvant Treatment With Toremifene in Hormone Receptor–Positive Breast Cancer: A Systematic Review of the Literature

Background: Endocrine therapy is an integral part of the backbone for hormone receptor–positive breast cancer treatment. Toremifene and tamoxifen are approved for hormone receptor–positive metastatic breast cancer. Tamoxifen is also appr...

JL05. Efficacy and Safety of the Granisetron Transdermal System (GTS) in Elderly Patients Receiving Multiday Chemotherapy Regimens

Background: Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of multiday chemotherapy that can lead to poor adherence, decreased quality of life, and compromised functional status. Commonly used routes of administr...

JL06. Hereditary Hemochromatosis: What the Nurse Practitioner Needs to Know

Background: Hereditary hemochromatosis is a disorder in which excessive iron absorption occurs, leading to an increase in iron deposits in major organs of the body and resulting in end organ damage. This is the most common genetic disord...

JL07. Intravenous Thiotepa for Meningeal Relapse of Breast Cancer: A Case Study

Treatment of meningeal carcinomatosis among breast cancer patients remains a clinical challenge, with a dismal outlook for long-term survival. Intrathecal thiotepa administration has been described in the literature; however, there are p...

JL08. Merkel Cell Carcinoma: Is It on Your Differential?

Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cutaneous malignancy with an atypical presentation, associated with the merkel cell polyomavirus (MCPyV) in 80% to 90% of cases. The vowel mnemonic, AEIOU is represe...

JL09. Personalized Medicine for Breast Cancer

Breast cancer is a biologically complex disease and remains one of the leading causes of cancer-related deaths in the world. Recent advances in genomic profiling of breast cancer tumors show promise in improving the outcomes of breast ca...

JL10. Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

Background: The subcutaneous (SC) route of administration for bortezomib was approved in the United  States in January 2012 in addition to the intravenous (IV) route. Although there is limited guidance in the US Prescribing Information r...

JL11. Don’t Fall for It! Preventing Falls in Patients with Cancer

The Oncology Nursing Society’s 2009–2013 research agenda highlights the need for greater attention to impaired physical functioning in inpatients with cancer because of the significant physical, psychological, and economic consequences. ...

JL12. Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes: Practical Take-Aways From Clinical Trials

Lenalidomide (LEN) is an oral immunomodulatory medication approved for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1‒risk myelodysplastic syndromes (MDS) with del(5q). In clinical trials of LEN...

JL13. Practical Guide to Management of Lenalidomide-Related Rash in Patients With MDS

Lenalidomide (LEN) is an oral immunomodulatory medication approved for patients with lower-risk, transfusion-dependent myelodysplastic syndromes (MDS) with del(5q) with or without additional cytogenetic abnormalities. The goal of LEN tre...

JL14. Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes

Over 10,000 individuals are diagnosed with myelodysplastic syndromes (MDS) annually in the United States. Bone marrow (BM) examination is essential for diagnosis, classification, and risk-stratification of MDS. The World Health Organizat...

ASH Highlights and Commentary: Multiple Myeloma

This supplement to JADPRO provides an overview of several abstracts that were presented at the 2019 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitione...

Methotrexate and Fluorouracil Toxicities: What Advanced Practitioners in Oncology Need to Know

Introduction The collaborative practice model is well known to improve patient care and enhance health-care delivery. Many different scenarios of collaborative practice have been described in the literature, often combining the teamwork...

Case Studies: Collaborative Practice In Action

Questions Answered About Glucarpidase

Questions Answered About Uridine Triacetate